An Open Label, Experimental Medicine Investigation of the Safety and Tolerability of 400 mg b.i.d. GSK2586184 in Patients With Moderate to Severely Active Ulcerative Colitis
Phase of Trial: Phase II
Latest Information Update: 02 May 2017
At a glance
- Drugs Solcitinib (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 10 Jun 2017 Biomarkers information updated
- 26 Aug 2014 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
- 03 Mar 2014 Status changed from recruiting to suspended, as reported by a Galapagos media release.